Flatiron Health today announced their planned presence at the American Society of Hematology (ASH) Annual Meeting and Exposition, including seven accepted abstracts for poster presentation and ...

for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase ...

However, they also respond more quickly to treatment, according to Cleveland Clinic. The most common type is diffuse large ...

Full House; actor Dave Coulier said he was diagnosed with stage 3 non-Hodgkin lymphoma in October and he has began ...

Researchers sought to determine whether liso-cel could be safely administered as an outpatient therapy in relapsed/refractory LBCL.

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...

Dave Coulier has been diagnosed with Stage 3 Non-Hodgkin lymphoma, after noticing a golf ball-sized swelling in his groin.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Two oral presentations on the ELM-1 and pivotal ELM-2 trials will feature new analyses in settings with significant unmet needs: one in patients with diffuse large B-cell lymphoma who progressed after ...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase ...

Brem, MD, an assistant clinical professor in the Division of Hematology/Oncology, School of Medicine at the University of ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...